Cargando…
Early-stage anaplastic lymphoma kinase (ALK)-positive lung cancer: a narrative review
BACKGROUND AND OBJECTIVE: While anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) are standard of care treatment for metastatic ALK-positive non-small cell lung cancer (NSCLC), the benefit of moving ALK inhibitors to earlier disease stages is unclear. The objective of this review is...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AME Publishing Company
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989809/ https://www.ncbi.nlm.nih.gov/pubmed/36895922 http://dx.doi.org/10.21037/tlcr-22-631 |